DCOY Stock Forecast: Decoy Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Decoy Therapeutics, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Decoy Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (63): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DCOY stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DCOY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Jan 2026 | Ladenburg Thalmann | Initiates | Buy | $2.50 |
| 11 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $4.00 |
| 25 Aug 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 June 2020 | Benchmark | Initiates | Speculative Buy | — |
| 27 Apr 2020 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DCOY.
This page is one stock. Monday covers all of them.
DCOY appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DCOY vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Decoy Therapeutics, Inc. returned −90.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DCOY analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- 3.8×
- Price / book
- 0.4×
- EV / EBITDA
- —
Cheaper than 97% of US stocks
Cheaper than 28% of US stocks
Cheaper than 88% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −376.7%
- Return on assets
- −69.0%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Decoy Therapeutics, Inc. has a market value of $2.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$14.4M.
Free cash flow in the twelve months to 30 June 2026: −$8.9M.
Trailing P/E: 0.0×.
Decoy Therapeutics, Inc. employs 11 people.
Data provided by Twelve Data
DCOY and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DCOY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Decoy Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DCOY
What is the DCOY stock price forecast for 2026-2027?
The median 12-month analyst price target for Decoy Therapeutics, Inc. is $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DCOY stock a buy right now?
Of the 1 analyst covering Decoy Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Decoy Therapeutics, Inc. 15 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DCOY?
As at 21 Nov 2026, Decoy Therapeutics, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (63 of 100).
Will DCOY stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $3, and Ticker Nerd's factor model ranks Decoy Therapeutics, Inc. 15 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DCOY stock forecast for 2030?
No analyst covering Decoy Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCOY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.
How has DCOY stock performed over the past year?
Decoy Therapeutics, Inc. returned -90.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Decoy Therapeutics, Inc. do?
Decoy Therapeutics Inc. is a pre-clinical biotechnology company focused on discovering and developing peptide conjugate therapeutics. Its core work centers on the IMP3ACT platform, which uses machine learning, artificial intelligence, and rapid synthesis methods to design and manufacture peptide-based drug candidates with improved targeting and development efficiency.
About Decoy Therapeutics, Inc.
Decoy Therapeutics Inc. is a pre-clinical biotechnology company focused on discovering and developing peptide conjugate therapeutics. Its core work centers on the IMP3ACT platform, which uses machine learning, artificial intelligence, and rapid synthesis methods to design and manufacture peptide-based drug candidates with improved targeting and development efficiency. The company’s current programs emphasize infectious diseases, with a particular focus on respiratory viruses, as well as oncology and other high-unmet-need areas. Decoy Therapeutics is developing Designable Multi-Antivirals, a class of antiviral candidates intended to address shared viral mechanisms across multiple virus families. The company also maintains a broader pipeline that includes legacy therapeutic assets alongside its newer antiviral efforts. Headquartered in Houston, Texas, Decoy Therapeutics operates as a research-driven biotechnology business aimed at advancing novel therapeutic platforms for difficult-to-treat diseases.
CEO Mr. Frederick E. Pierce II · 11 employees · United States · https://decoytx.com